ClinConnect ClinConnect Logo
Search / Trial NCT06692192

The RECAP2 Study: Midazolam and Psilocybin

Launched by UNIVERSITY OF WISCONSIN, MADISON · Nov 15, 2024

Trial Information

Current as of July 09, 2025

Recruiting

Keywords

Sub Optimal Wellbeing

ClinConnect Summary

The RECAP2 Study is a clinical trial designed to explore how a substance called psilocybin, when combined with a medication called midazolam, can improve emotional wellbeing in individuals who have experienced a slight decline in their mood. The researchers want to find out what dose of psilocybin works best for enhancing wellbeing by looking at how it affects the brain's ability to adapt and change.

To participate, individuals need to be between 18 and 70 years old, in good physical health, and able to speak English. They should have a modest decrease in their feeling of wellbeing but not have any major mood or anxiety disorders. Participants will receive one of four different combinations of medications and will undergo various assessments, including an MRI scan and questionnaires. It’s important to note that this trial is not yet recruiting, so interested individuals will need to wait for further announcements.

Gender

ALL

Eligibility criteria

  • Inclusion Criteria:
  • Age 18 to 65 years at screening, of any identified gender and racial/ethnic group
  • Physically healthy; does not meet criteria for an exclusionary medical condition
  • English-speaking (able to provide consent and complete questionnaires)
  • Modest decrement in self-reported wellbeing without the presence of a DSM-5 Axis I mood or anxiety disorder
  • Able to undergo magnetic resonance imaging (MRI) and transcranial magnetic stimulation (TMS)
  • Exclusion Criteria:
  • Exclusionary DSM-5 psychiatric diagnosis and/or active suicidal ideation
  • Exclusionary medical conditions
  • Clinically significant safety lab abnormalities (i.e., Complete Blood Count with Differential, Comprehensive Metabolic Panel, and urinalysis)
  • Clinically significant electrocardiogram (ECG)
  • Use of psychotropic or CNS-altering medications within 3 months of screening
  • Hypertension or tachycardia

About University Of Wisconsin, Madison

The University of Wisconsin-Madison is a leading research institution renowned for its commitment to advancing healthcare through innovative clinical trials. With a strong emphasis on interdisciplinary collaboration, the university leverages its extensive resources, including cutting-edge facilities and a diverse pool of expert researchers, to conduct rigorous studies that address critical health challenges. The institution's focus on translating research findings into practical applications fosters the development of new treatments and interventions, ultimately contributing to improved patient outcomes and public health initiatives. As a sponsor of clinical trials, the University of Wisconsin-Madison is dedicated to upholding the highest ethical standards and ensuring participant safety throughout the research process.

Locations

Madison, Wisconsin, United States

Patients applied

0 patients applied

Trial Officials

Charles Raison, MD

Principal Investigator

University of Wisconsin, Madison

Timeline

First submit

Trial launched

Trial updated

Estimated completion

Not reported